ESMO Presidential Symposium: Final overall survival analysis from the FLAURA trial
Released Thursday, 26th September 2019
Good episode? Give it some love!
ESMO Presidential Symposium: Final overall survival analysis from the FLAURA trial
ESMO Presidential Symposium: Final overall survival analysis from the FLAURA trial
Thursday, 26th September 2019
Good episode? Give it some love!
Rate Episode
Osimertinib vs comparator EGFR-TKI as first-line treatment for EGFRm advanced NSCLC (FLAURA): Final overall survival analysis.The phase III trial Osimertinib vs comparator EGFR-TKI as first-line treatment for EGFRm advanced NSCLC (FLAURA) showed a significant increase in progression free survival. In the now available finale survival analysis also the overall survival showed a statistical significant increase.
Expert: Suresh S. Ramalingam, Winship Cancer Institute of Emory University, Atlanta, GA
Show More
Rate
From The Podcast
ESMO Open
ESMO Open is the European Society for Medical Oncology’s online-only, peer-reviewed Open Access journal, dedicated to publishing high-quality medical research and educational content from all disciplines of oncology, with a focus on innovative clinical and translational cancer research.Join Podchaser to...
- Rate podcasts and episodes
- Follow podcasts and creators
- Create podcast and episode lists
- & much more
Episode Tags
Do you host or manage this podcast?
Claim and edit this page to your liking.
,Claim and edit this page to your liking.
Unlock more with Podchaser Pro
- Audience Insights
- Contact Information
- Demographics
- Charts
- Sponsor History
- and More!
- Account
- Register
- Log In
- Find Friends
- Resources
- Help Center
- Blog
- API
Podchaser is the ultimate destination for podcast data, search, and discovery. Learn More
- © 2024 Podchaser, Inc.
- Privacy Policy
- Terms of Service
- Contact Us